On Monday, GlycoMimetics Inc (NASDAQ:GLYC) stock opened its trade at $11.97 and after floating in a range of $10.79 to $12.90, settled at $11.01. GLYC's total short interest was 536,800 shares in May as published by FINRA. The stock witnessed 144.12% gains, 73.11% gains and 68.61% gains for the 1-month, 3-month and 6-month period, respectively. For the last month, company shares are 19.05%. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite. The company has a 50 day moving average price of $4.92 and a 200-day moving average price of $5.85. (GLYC) have 20.60 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.
03/01/2016 - GlycoMimetics Inc had its " rating reiterated by analysts at Jefferies. Analysts are forecasting earnings of $-0.36 on a per share basis this quarter. The average analysts gave this company a mean recommendation of 1.40. (GLYC) were valued at $11.01 and moved -13.71% as of a recent closing trade. The Return on Equity ratio of GlycoMimetics, Inc.
Since the beginning of the calendar year, the stock is 80.49%. Wellington Management Group LLP increased its stake in GlycoMimetics by 14.9% in the first quarter. In contrast, the average volume was 1.04 million shares. Russell Investments Group Ltd. purchased a new position in shares of GlycoMimetics during the fourth quarter valued at approximately $172,000. Sphera Funds Management LTD. now owns 775,796 shares of the biotechnology company's stock valued at $4,213,000 after buying an additional 30,000 shares during the last quarter. The company has Beta Value of 2.98 and ATR value of 1.02. State Street Corp increased its stake in GlycoMimetics by 2.6% in the fourth quarter. (NASDAQ:GLYC), with 4 analysts believing it is a strong buy.More news: Isaiah Thomas to see specialists about hip injury Monday
More news: 23-year-old man arrested in connection with Manchester terror attack
More news: West Ham United should act fast and sign Jermain Defoe
Some buy side analysts are also providing their Analysis on GlycoMimetics, Inc., where 3 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. Zacks Investment Research lowered shares of GlycoMimetics from a "hold" rating to a "sell" rating in a report on Friday, March 3rd. GlycoMimetics now has an average rating of "Buy" and a consensus price target of $11.94. This company shares are 13.53% off its target price of $12.5 and the current market capitalization stands at $226.81M.
WARNING: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another publication, it was illegally copied and republished in violation of US & global trademark and copyright legislation.
GlycoMimetics, Inc is a clinical-stage biotechnology company. EyeGate Pharmaceuticals, Inc. (EYEG) revealed that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. under the Company's License Contract with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company's EyeGate II Delivery System and EGP-437 combination product in post-operative ocular inflammation and pain in ocular surgery patients. The Firm operates through the identification and development of glycomimetic compounds segment.